Fig. 1From: Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug actOrphan drugs for rare rheumatologic disorders – number of orphan drug designations (open box) and FDA approvals (black box) per yearBack to article page
